Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients with Melanoma or Genitourinary Cancer

Status: active

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.

Inclusion Criteria

PROJECT 1: Diagnosis of any stage melanoma, non-small cell lung cancer or genitourinary (GU) malignancies
PROJECT 2 and 3: Diagnosis of any cancer type
Treatment with any ICPI agent
Ability to understand and willingness to sign an informed consent form and rate on surveys
Life expectancy > 4 months
PROJECT 1: ICPI-related diarrhea and/or colitis of any grade with or without concurrent non-GI toxicity as the toxicity group
PROJECT 1: Patients with no organ toxicity as the control group
PROJECT 2: ICPI-related colitis and/or diarrhea of grade >= 2 as GI toxicity (initial episode or recurrence) receiving standard treatment of immunosuppressive agents (steroid, infliximab, vedolizumab, or ustekinumab) any time during the colitis disease course until sustained resolution of GI toxicity, or one- year time point after enrollment
PROJECT 3: ICPI-related colitis and/or diarrhea of peak grade >= 2 as GI toxicity without involvement of non-GI toxicity within 45 days prior to FMT
PROJECT 3: ICPI-related colitis and/or diarrhea of grade >= 2 within 45 days prior to FMT with ANY of the following characteristics: * refractory to treatment of steroid and two doses of non-steroidal immunosuppressants e.g. infliximab and/or vedolizumab or ustekinumab * contraindication for immunosuppressive treatment * recurrence after successful initial treatment * recurrent symptoms once steroid is tapered down/off or diarrhea/colitis symptoms are steroid dependent, or * patients with a history of refractory ICPI-related colitis and/or diarrhea to medical treatment, even if they have improved symptoms from supportive care within 45 days prior to FMT
PROJECT 3: No concern for active concomitant GI infection for the ICPI diarrhea/colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation

Exclusion Criteria

Age younger than 18 years
History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
Pregnant and breastfeeding women
Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of ‘no pregnancy’ status (e.g. blood or imaging) within 30 days prior to date of study treatment
PROJECT 3: Patients with active bacterial or fungal infection
PROJECT 3: Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire

PRIMARY OBJECTIVES:

I. To compare the difference in stool microbiome pattern between patients who develop immune-checkpoint inhibitor (ICPI)-related colitis and patients who don’t develop ICPI-related colitis.

II. To compare the difference in stool microbiome pattern in patients who developed ICPI-related colitis before and after colitis medical treatment.

III. To assess the safety and tolerability and efficacy of fecal microbiota transplantation (FMT).

SECONDARY OBJECTIVES:

I. To identify and characterize immune profile and genetic factors associated with onset of ICPI-related colitis in blood and colon tissue.

II. To identify and characterize immune profile and genetic factors in blood and colon tissue that are associated with quick response of ICPI-related colitis to medical treatment.

III. To characterize the endoscopic and histologic features of ICPI-related colitis before and after medical treatment.

IV. To document the changes of ICPI-related symptoms and the impact on functioning and quality of life (QoL) from fecal microbiota transplantation by patient-reported outcomes (PRO).

V. To assess stool microbiome and cytokine features that are associated with good response to fecal microbiota transplantation.

VI. To assess the factors in genetic/immune profile obtained from blood and colon tissue that are associated with good response to fecal microbiota transplantation.

VII. To characterize the endoscopic and histologic features of ICPI-related colitis before and after fecal microbiota transplantation.

EXPLORATORY OBJECTIVES:

I. To identify and characterize immune profile and genetic factors associated with onset of ICPI-related colitis in inflamed colonic mucosa and its matched normal mucosa.

II. To characterize the immune profile and genetic factors from the colon tissue in these colitis patients among different histological subtypes.

III. To assess the pattern of stool microbiome that is associated with good tumor response to ICPI treatment.

IV. To assess the association between stool inflammatory markers (i.e. lactoferrin and calprotectin) and the severity of endoscopic/histologic inflammation.

V. To assess the sensitivity and specificity of stool inflammatory markers (i.e. lactoferrin and calprotectin) as an indicators of ICPI-relate colitis response to treatment.

VI. To assess the microbiome pattern that triggers the infections on immunosuppressant treatment for ICPI colitis.

VII. To study the efficacy and/ or benefit of PuraStat gel in the healing of mucosal ulcers and its hemostatic effect on bleeding lesions, and to compare these results with a historic cohort that was not treated with PuraStat.

OUTLINE:

PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.

PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy at 1 and/or 2 months after treatment. Additionally, patients may also receive PuraStat gel topically to inflamed areas at the discretion of the treating endoscopist. Patients also undergo collection of stool, blood, and tissue samples.

PROJECT 3: Patients undergo fecal microbiota transplant (FMT). Additionally, patients undergo collection of stool and blood samples throughout the study.

After completion of study, patients are followed up periodically.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients with Melanoma or Genitourinary Cancer

Inclusion Criteria

Exclusion Criteria

United States

Texas

Houston

Have a question?
We're here to help

Which trials are right for you?

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients with Melanoma or Genitourinary Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help